Kim Yunee, Kislinger Thomas
Department of Medical Biophysics, University of Toronto, Toronto, Canada M5G 1L7.
Department of Medical Biophysics, University of Toronto, Toronto, Canada M5G 1L7 ; Princess Margaret Cancer Center, University Health Network, Toronto, Canada M5G 1L7.
Genome Med. 2013 Jun 28;5(6):56. doi: 10.1186/gm460. eCollection 2013.
The ability to distinguish indolent from aggressive prostate tumors remains one of the greatest challenges in the management of this disease. Ongoing efforts to establish a panel of molecular signatures, comprising gene expression profiles, proteins, epigenetic patterns, or a combination of these alterations, are being propelled by rapid advancements in 'omics' technologies. The identification of such biomarkers in biological fluids is an especially attractive goal for clinical applications. Here, we summarize recent progress in the identification of candidate prognostic biomarkers of prostate cancer using biological fluid samples.
区分惰性前列腺肿瘤和侵袭性前列腺肿瘤的能力仍然是这种疾病管理中最大的挑战之一。随着“组学”技术的快速发展，人们正在不断努力建立一组分子特征，包括基因表达谱、蛋白质、表观遗传模式或这些改变的组合。在生物体液中鉴定此类生物标志物是临床应用中一个特别有吸引力的目标。在这里，我们总结了使用生物体液样本鉴定前列腺癌候选预后生物标志物的最新进展。
